CXCR4 and central nervous system cancer: Moreover, in gliomas characterized by high vasculogenic potential, the incorporation of EPCs into blood vessels was associated with CXCL12 secretion, whereas the CXCR4 antagonist AMD3100 abrogated the ability of CXCL12 to trigger EPC incorporation into the tumor vasculature [169].